Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD

NCT05068284 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05068284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05068284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2022
Completion date
July 20, 2023
Enrollment
176 (actual)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease